Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 83.12 3.02% 2.44
ALNY closed up 3.02 percent on Friday, January 18, 2019, on 1.12 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical ALNY trend table...

Date Alert Name Type % Chg
Jan 18 Multiple of Ten Bullish Other 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Narrow Range Bar Range Contraction 3.02%
Jan 17 NR7 Range Contraction 3.02%
Jan 17 Multiple of Ten Bullish Other 3.02%
Jan 17 Wide Bands Range Expansion 3.02%
Jan 16 Wide Bands Range Expansion 2.77%
Jan 15 Volume Surge Other 3.32%
Jan 15 Multiple of Ten Bullish Other 3.32%

Older signals for ALNY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Is ALNY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 153.99
52 Week Low 60.27
Average Volume 953,908
200-Day Moving Average 91.4417
50-Day Moving Average 75.7368
20-Day Moving Average 76.614
10-Day Moving Average 83.933
Average True Range 4.6021
ADX 19.19
+DI 27.2049
-DI 21.6026
Chandelier Exit (Long, 3 ATRs ) 76.8937
Chandelier Exit (Short, 3 ATRs ) 74.0763
Upper Bollinger Band 92.9603
Lower Bollinger Band 60.2677
Percent B (%b) 0.7
BandWidth 42.671835
MACD Line 2.4116
MACD Signal Line 1.9191
MACD Histogram 0.4925
Fundamentals Value
Market Cap 7.62 Billion
Num Shares 91.7 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -16.23
Price-to-Sales 159.14
Price-to-Book 9.35
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 89.39
Resistance 3 (R3) 88.71 85.95 88.35
Resistance 2 (R2) 85.95 84.35 86.29 88.00
Resistance 1 (R1) 84.53 83.36 85.24 85.21 87.65
Pivot Point 81.77 81.77 82.12 82.11 81.77
Support 1 (S1) 80.35 80.17 81.06 81.03 78.59
Support 2 (S2) 77.59 79.18 77.93 78.24
Support 3 (S3) 76.17 77.59 77.90
Support 4 (S4) 76.85